Description
Genferon Lite Pharmacodynamics
Recombinant human interferon alfa-2b, produced by Escherichia coli strain, in which human interferon alfa-2b gene was inserted by genetic engineering methods, is the component of Genferon® light. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. Antiviral effect is mediated by activation of a number of intracellular enzymes that inhibit viral replication. Immunomodulatory effect is primarily manifested by strengthening the cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of
CD8+ T-rollers, NK-cells (natural killers), increased differentiation. B-lymphocytes and their production of antibodies, activation of monocytic-macrophage system and phagocytosis, as well as increased expression of histocompatibility complex type I molecules, which increases the probability of recognition of infected cells by immune system cells. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane provides their active participation in liquidation of pathological foci; besides, due to the influence of interferon, restoration of production of secretory immunoglobulin A is achieved. Antimicrobial effect is mediated by immune system reactions enhanced under the influence of interferon.
Taurine promotes normalization of metabolic processes and tissue regeneration, has membranostabilizing and immunomodulatory effects. As a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to pathological processes. Taurine helps to preserve the biological activity of interferon, increasing the therapeutic effect of the drug.
Indications
Prevention and treatment of influenza and acute respiratory viral infections in adults and children over 14 years.
Contraindications
Hypersensitivity to interferon alfa-2b or other drug components.
Childhood age less than 14 years.
Dosage and administration method
- The drug is applied intranasally by aerosol administration of 1 dose (1 dose = 1 short press on the doser).
- At the first signs of the disease Genferon® Lite is injected intranasally during 5 days in one dose (one pressure on the pipette) into each nasal passage 3 times a day (one dose is approximately 50 000 IU of interferon alfa, daily dose should not exceed 500 000 IU).
- If you have contact with a patient with acute respiratory infections and / or hypothermia, the drug is administered according to the above scheme 2 times a day for 5-7 days.
- Prophylactic courses are repeated if necessary.
- Instructions for use of the spray:
1. Remove the protective cap.
2. Before using for the first time, press the dispenser several times until a thin stream appears.
3. When using, keep the bottle upright.
4. Inject the product into each nasal passage by pressing the pipette once, alternately.
5. After use, close the dispenser with the protective cap. - Individual use is recommended to avoid the spread of infection.
